Clinical Trials Directory

Trials / Terminated

TerminatedNCT00574717

Enhancement of Emmetropization in Hyperopic Infants

Status
Terminated
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Ohio State University · Academic / Other
Sex
All
Age
8 Weeks – 20 Weeks
Healthy volunteers
Not accepted

Summary

To determine if wearing a moderate spectacle under-correction (3.00D) and performing activities designed to stimulate accurate accommodation during a 15-month period will enhance emmetropization in highly hyperopic (between +5.00D and +7.00D) 3-month old infants.

Detailed description

The purpose of the project is to determine if emmetropization can be enhanced in very farsighted babies. We will give them glasses with a partial correction, an amount that is less than their full degree of farsightedness but enough to put them in the zone of effective emmetropization. This 'boost' is meant to enable very farsighted babies to use their eyes in a normal way and emmetropize as normal infants. This partial correction would be given at 3 months of age for a period of up to 15 months. A program of visual engagement is also provided in order to encourage the normal development and use of accommodation. As changes in farsightedness occur, the power of the glasses will be reduced at follow up appointments to keep the farsightedness within the zone of effective emmetropization. Once an infant reaches a normal amount of farsightedness, the glasses would be discontinued.

Conditions

Interventions

TypeNameDescription
PROCEDURESpectaclesInfants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.

Timeline

Start date
2007-12-01
Primary completion
2010-09-01
Completion
2010-09-01
First posted
2007-12-17
Last updated
2012-10-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00574717. Inclusion in this directory is not an endorsement.